Ashvattha Therapeutics holds the exclusive rights to a novel hydroxyl dendrimer technology developed at Johns Hopkins University enabling a new class of targeted therapies previously unachievable with traditional drug moieties. Ashvattha are commercializing the technology through new entities established to develop therapeutic opportunities within specific fields and enabled through the use of our dendrimer platform.
Company HQ State:
Company HQ Country:
Main Therapeutic Focus:
Lead Product in Development:
OP-101 through wholly owned subsidiary, Orpheris
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):